San Francisco—A new agent shows promise in reducing bone loss and delaying progression of disease in men with advanced prostate cancer that no longer responds to hormone therapy, according to findings presented here at the annual meeting of the American Society of Clinical Oncology. Like other new therapeutics that are emerging in cancer treatment, this experimental drug is intended to target one of the specific molecular pathways that allow the cancerous cells to survive, proliferate, and spread through the body.
Stephenson J. Experimental Prostate Cancer Drugs Slow Disease Progression. JAMA. 2001;286(1):34. doi:10.1001/jama.286.1.34-JMN0704-3-1